Molecular Epidemiology of Ceftriaxone Non-Susceptible Enterobacterales Isolates in an Academic Medical Center in the United States.
Enterobacteriaceae
Check-Points
ESBL
ampC beta-lactamase
antimicrobial resistance
extended-spectrum beta-lactamase
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
11 Aug 2019
11 Aug 2019
Historique:
received:
20
05
2019
pubmed:
12
8
2019
medline:
12
8
2019
entrez:
12
8
2019
Statut:
ppublish
Résumé
Knowledge of whether Enterobacterales are not susceptible to ceftriaxone without understanding the underlying resistance mechanisms may not be sufficient to direct appropriate treatment decisions. As an example, extended-spectrum β-lactamase (ESBL)-producing organisms almost uniformly display non-susceptibility to ceftriaxone. Regardless of susceptibility to piperacillin-tazobactam or cefepime, carbapenem antibiotics are the treatment of choice for invasive infections. No such guidance exists for ceftriaxone non-susceptible organisms with mechanisms other than ESBL production. We sought to investigate the molecular epidemiology of ceftriaxone non-susceptible Enterobacterales. All consecutive Escherichia coli, Klebsiellapneumoniae, Klebsiella oxytoca, or Proteus mirabilis clinical isolates with ceftriaxone MICs of ≥2 mcg/mL from unique patients at a United States hospital over an 8-month period were evaluated for β-lactamase genes using a DNA microarray-based assay. Of 1929 isolates, 482 (25%) had ceftriaxone MICs of ≥2 mcg/mL and were not resistant to any carbapenem antibiotics. Of the 482 isolates, ESBL (blaCTX-M, blaSHV, blaTEM) and/or plasmid-mediated ampC (p-ampC) genes were identified in 376 (78%). ESBL genes were identified in 310 (82.4%), p-ampC genes in 2 (0.5%), and both ESBL and p-ampC genes in 64 (17.0%) of the 376 organisms. There were 211 (56%), 120 (32%), 41 (11%), and 4 (1%) isolates with 1, 2, 3, or 4 or more ESBL or p-ampC genes. The most common ESBL genes were of the blaCTX-M-1 group (includes blaCTX-M-15) and the most common p-ampC gene was the blaCMY-2. There is considerable diversity in the molecular epidemiology of ceftriaxone non-susceptible Enterobacterales. An understanding of this diversity can improve antibiotic decision-making.
Sections du résumé
BACKGROUND
BACKGROUND
Knowledge of whether Enterobacterales are not susceptible to ceftriaxone without understanding the underlying resistance mechanisms may not be sufficient to direct appropriate treatment decisions. As an example, extended-spectrum β-lactamase (ESBL)-producing organisms almost uniformly display non-susceptibility to ceftriaxone. Regardless of susceptibility to piperacillin-tazobactam or cefepime, carbapenem antibiotics are the treatment of choice for invasive infections. No such guidance exists for ceftriaxone non-susceptible organisms with mechanisms other than ESBL production. We sought to investigate the molecular epidemiology of ceftriaxone non-susceptible Enterobacterales.
METHODS
METHODS
All consecutive Escherichia coli, Klebsiellapneumoniae, Klebsiella oxytoca, or Proteus mirabilis clinical isolates with ceftriaxone MICs of ≥2 mcg/mL from unique patients at a United States hospital over an 8-month period were evaluated for β-lactamase genes using a DNA microarray-based assay.
RESULTS
RESULTS
Of 1929 isolates, 482 (25%) had ceftriaxone MICs of ≥2 mcg/mL and were not resistant to any carbapenem antibiotics. Of the 482 isolates, ESBL (blaCTX-M, blaSHV, blaTEM) and/or plasmid-mediated ampC (p-ampC) genes were identified in 376 (78%). ESBL genes were identified in 310 (82.4%), p-ampC genes in 2 (0.5%), and both ESBL and p-ampC genes in 64 (17.0%) of the 376 organisms. There were 211 (56%), 120 (32%), 41 (11%), and 4 (1%) isolates with 1, 2, 3, or 4 or more ESBL or p-ampC genes. The most common ESBL genes were of the blaCTX-M-1 group (includes blaCTX-M-15) and the most common p-ampC gene was the blaCMY-2.
CONCLUSIONS
CONCLUSIONS
There is considerable diversity in the molecular epidemiology of ceftriaxone non-susceptible Enterobacterales. An understanding of this diversity can improve antibiotic decision-making.
Identifiants
pubmed: 31401649
pii: ofz353
doi: 10.1093/ofid/ofz353
pmc: PMC6736082
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz353Subventions
Organisme : NIAID NIH HHS
ID : K23 AI127935
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Pathology. 2015 Jun;47(4):386-8
pubmed: 25938360
Open Forum Infect Dis. 2019 Jul 1;6(7):
pubmed: 31363762
J Clin Microbiol. 2003 Jan;41(1):155-8
pubmed: 12517841
Diagn Microbiol Infect Dis. 2015 Sep;83(1):56-8
pubmed: 26099646
Infection. 1989 Sep-Oct;17(5):316-21
pubmed: 2689349
J Clin Microbiol. 2009 Aug;47(8):2419-25
pubmed: 19494061
Antimicrob Agents Chemother. 2004 Feb;48(2):533-7
pubmed: 14742206
Antimicrob Agents Chemother. 2002 Jan;46(1):1-11
pubmed: 11751104
Lancet Infect Dis. 2008 Mar;8(3):159-66
pubmed: 18291338
J Clin Microbiol. 2011 Apr;49(4):1608-13
pubmed: 21325547
Clin Microbiol Rev. 2005 Oct;18(4):657-86
pubmed: 16223952
Diagn Microbiol Infect Dis. 1998 Jul;31(3):461-6
pubmed: 9635237
Clin Infect Dis. 2009 Mar 15;48(6):739-44
pubmed: 19187027
JAMA. 2018 Sep 11;320(10):984-994
pubmed: 30208454
J Antimicrob Chemother. 2018 Mar 1;73(3):634-642
pubmed: 29253152
Antimicrob Agents Chemother. 2012 Apr;56(4):1870-6
pubmed: 22290945
Antimicrob Agents Chemother. 2008 Nov;52(11):3909-14
pubmed: 18765688
J Antimicrob Chemother. 2017 Aug 1;72(8):2145-2155
pubmed: 28541467
J Clin Microbiol. 2000 May;38(5):1791-6
pubmed: 10790101
Open Forum Infect Dis. 2019 Feb 19;6(3):ofz064
pubmed: 30895204
Antimicrob Agents Chemother. 2008 Mar;52(3):995-1000
pubmed: 18086837
Clin Infect Dis. 2019 Sep 27;69(8):1446-1455
pubmed: 30838380
Lancet Infect Dis. 2017 Jan;17(1):78-85
pubmed: 27751772
Infect Control Hosp Epidemiol. 2015 Aug;36(8):981-5
pubmed: 25990361
J Antimicrob Chemother. 2016 Feb;71(2):296-306
pubmed: 26542304
Antimicrob Agents Chemother. 2016 May 23;60(6):3462-9
pubmed: 27021322